Vaxxinity (website removed all info intentionally*)

COVID booster

clearingimmunotherapy

vaxxinity.com·Florida, United States; New York City, New York, United States·$78M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-4XZK

Summary · Eternal Search editorial

Vaxxinity (website removed all info intentionally*) COVID booster

The visible site text identifies Vaxxinity and links to pages for its science, platform, publications, lab news, and news releases. The page highlights that Vaxxinity's COVID booster succeeded in Phase 3 and describes it as long-lasting, well tolerated, cost-effective, and effective against emerging variants with no frozen cold chain, mRNA, or spike protein.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite14

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Vaxxinity (website removed all info intentionally*) — Near-term readout · Bottom quartile. Derived deterministically from 9 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webvaxxinity.com

HQFlorida, United States; New York City, New York, United States

Publications

15 on file

012026Active immunization against myostatin and activin A improves skeletal muscle performance in growth hormone-deficient mice.GeroScience→022025Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial—→032025Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.EClinicalMedicine→042025Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.Communications medicine→052024VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.Journal of lipid research→062024Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial—→072024Active Immunotherapy for the Prevention of Alzheimer's and Parkinson's Disease—→082024VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys—→092023Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.EBioMedicine→102023RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.Vaccines→112022A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.The Journal of clinical investigation→122022A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine—→132022Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut.Acta neuropathologica→142022A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.Emerging microbes & infections→152022High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.The Journal of infectious diseases→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Vaxxinity (website removed all info intentionally*)

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.